Lenvatinib applicability in the therapeutic strategy of patients with hepatocellular carcinoma.
作者信息
Merle Philippe
机构信息
Hepatology Unit, University Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France.
出版信息
Hepatobiliary Surg Nutr. 2023 Apr 10;12(2):248-251. doi: 10.21037/hbsn-23-91. Epub 2023 Mar 27.
Abstract
摘要
相似文献
1
Lenvatinib applicability in the therapeutic strategy of patients with hepatocellular carcinoma.乐伐替尼在肝细胞癌患者治疗策略中的适用性。
Hepatobiliary Surg Nutr. 2023 Apr 10;12(2):248-251. doi: 10.21037/hbsn-23-91. Epub 2023 Mar 27.
2
IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin.干扰素调节因子2通过调控β-连环蛋白来调节肝细胞癌（HCC）的细胞存活及对乐伐替尼的敏感性。
Transl Oncol. 2021 Jun;14(6):101059. doi: 10.1016/j.tranon.2021.101059. Epub 2021 Mar 15.
3
SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway.SREBP2 抑制剂 betulin 通过抑制 mTOR/IL-1β 通路增强肝癌细胞对 lenvatinib 的敏感性。
Acta Biochim Biophys Sin (Shanghai). 2023 Jul 11;55(9):1479-1486. doi: 10.3724/abbs.2023122.
4
Focal adhesion kinase confers lenvatinib resistance in hepatocellular carcinoma via the regulation of lysine-deficient kinase 1.焦点黏着激酶通过调节赖氨酸缺陷型激酶 1 赋予肝癌对乐伐替尼的耐药性。
Mol Carcinog. 2024 Jan;63(1):173-189. doi: 10.1002/mc.23644. Epub 2023 Oct 3.
5
Curcumol Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells.姜黄素增强仑伐替尼对肝癌细胞的抗肿瘤作用。
Discov Med. 2024 Jan;36(180):199-208. doi: 10.24976/Discov.Med.202436180.19.
6
Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells .维生素 C 和仑伐替尼联合作用增强肝癌细胞的抗肿瘤效应。
PeerJ. 2023 Jan 25;11:e14610. doi: 10.7717/peerj.14610. eCollection 2023.
7
Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.经动脉化疗栓塞术联合仑伐替尼对比经动脉化疗栓塞术联合索拉非尼作为伴门静脉癌栓的肝细胞癌一线治疗的前瞻性随机研究。
Cancer. 2021 Oct 15;127(20):3782-3793. doi: 10.1002/cncr.33677. Epub 2021 Jul 8.
8
Targeting Hedgehog signalling in CD133-positive hepatocellular carcinoma: improving Lenvatinib therapeutic efficiency.靶向 CD133 阳性肝癌中的 Hedgehog 信号通路：提高仑伐替尼的治疗效果。
Med Oncol. 2021 Mar 17;38(4):41. doi: 10.1007/s12032-021-01487-w.
9
FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.FDA 补充批准概要：仑伐替尼治疗不可切除肝细胞癌。
Oncologist. 2021 Mar;26(3):e484-e491. doi: 10.1002/onco.13566. Epub 2020 Nov 10.
10
Exploring the Therapeutic Potential of Lenvatinib: A Complete Pathological Response in an Operable Case of Hepatocellular Carcinoma.探索乐伐替尼的治疗潜力：1例可手术切除的肝细胞癌病例出现完全病理缓解
Cureus. 2024 Jul 9;16(7):e64166. doi: 10.7759/cureus.64166. eCollection 2024 Jul.
引用本文的文献
1
Simulating the tumor microenvironment-advances in building a vascularized model of hepatocellular carcinoma through 3D bioprinting.模拟肿瘤微环境——通过3D生物打印构建血管化肝细胞癌模型的进展
Hepatobiliary Surg Nutr. 2024 Oct 1;13(5):882-884. doi: 10.21037/hbsn-24-154. Epub 2024 Sep 26.
2
may serve as a predictive marker for the efficacy of lenvatinib in patients with HBV-related early-stage hepatocellular carcinoma following partial hepatectomy: a retrospective cohort study.可作为肝部分切除术后乙肝相关早期肝细胞癌患者使用乐伐替尼疗效的预测标志物：一项回顾性队列研究
J Gastrointest Oncol. 2023 Dec 31;14(6):2479-2499. doi: 10.21037/jgo-23-942. Epub 2023 Dec 27.
本文引用的文献
1
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial.帕博利珠单抗作为晚期肝细胞癌的二线治疗：3期KEYNOTE-240试验的长期随访
Liver Cancer. 2023 Feb 14;12(4):309-320. doi: 10.1159/000529636. eCollection 2023 Sep.
2
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.378 例不可切除肝细胞癌患者中仑伐替尼联合 PD-1 抑制剂的真实世界疗效和预后因素。
Hepatol Int. 2023 Jun;17(3):709-719. doi: 10.1007/s12072-022-10480-y. Epub 2023 Feb 8.
3
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.卡博替尼联合阿替利珠单抗与索拉非尼治疗晚期肝细胞癌（COSMIC-312）：一项多中心、开放标签、随机、III 期临床试验。
Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.
4
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.纳武利尤单抗对比索拉非尼用于治疗晚期肝细胞癌（CheckMate 459）：一项随机、多中心、开放标签、III 期临床试验。
Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.
5
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.IMbrave150研究的更新疗效和安全性数据：阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗不可切除肝细胞癌。
J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.
6
Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma.专家共识：仑伐替尼治疗肝细胞癌不良反应的管理。
J Gastroenterol Hepatol. 2022 Mar;37(3):428-439. doi: 10.1111/jgh.15727. Epub 2021 Nov 17.
7
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
8
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.帕博利珠单抗作为 KEYNOTE-240 中晚期肝细胞癌二线治疗的疗效：一项随机、双盲、III 期试验。
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
9
Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma.酪氨酸激酶抑制剂相关不良反应的管理：改善肝细胞癌患者的预后。
Cancer Treat Rev. 2019 Jul;77:20-28. doi: 10.1016/j.ctrv.2019.05.004. Epub 2019 May 15.
10
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.卡博替尼治疗晚期和进展性肝细胞癌患者。
N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.
Zotero 插件